Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

OBJECTIVE Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population. RESEARCH DESIGN AND METHODS In a multicenter,case-control,retrospective,observational study,sitagliptin,an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex.All patients had pneumonia and exhibited oxygen saturation < 95% when breathing ambient air or when receivingoxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020. RESULTSOf the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18%vs. 37%of deceased patient);hazard ratio 0.44 [95% CI 0.29–0.66];P<0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients;P<0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients;P<0.0008) compared with patients receiving standard of care, respectively. CONCLUSIONS In this multicenter, case-control,retrospective,observational study of patients withtype 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinicaloutcomesascomparedwithstandard-of-caretreatment.Theeffects of sitagliptinin patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.